Stockscreener 앱 받기
2.93
3.53%
0.10
전일 마감가:
$2.83
열려 있는:
$2.81
하루 거래량:
16,982
Relative Volume:
0.09
시가총액:
$1.76M
수익:
$5.66M
순이익/손실:
$-15.88M
주가수익비율:
-0.259
EPS:
-11.3134
순현금흐름:
$-10.93M
1주 성능:
-19.95%
1개월 성능:
-63.05%
6개월 성능:
-91.16%
1년 성능:
-92.46%
1일 변동 폭
$2.75
$2.974
1주일 범위
$2.66
$3.73
52주 변동 폭
$2.66
$80.70
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
명칭
Bioaffinity Technologies Inc
전화
210-698-5334
주소
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, NTRA, A, IQV
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
2.93 | 1.76M | 5.66M | -15.88M | -10.93M | -11.31 |
TMO
Thermo Fisher Scientific Inc
|
693.03 | 256.25B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
233.33 | 164.03B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.88 | 58.94B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
177.47 | 50.03B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
274.97 | 45.26B | 16.63B | 1.39B | 2.12B | 8.0674 |
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
bioAffinity Technologies, Inc. (BIAF) stock price, news, quote and history - Yahoo Finance Australia
bioAffinity Technologies, Inc. (BIAF) Interactive Stock Chart - Yahoo! Finance Canada
bioAffinity Technologies, Inc. (BIAF) latest stock news and headlines - Yahoo Finance UK
A test of lung cells gives doctors a “likely” or “unlikely” cancer-risk result. - Stock Titan
A test in development found multiple lung-inflammation markers in mucus. bioAffinity will present the research. - Stock Titan
Stockholders face dilution under bioAffinity (BIAF)'s proposed discounted non-public offerings. - Stock Titan
bioAffinity Technologies Completes New $4 Million Financing - The Globe and Mail
Form 424B5 bioAffinity Technologies Inc For: 10 October By Investing.com - Investing.com Canada
bioAffinity Technologies closes $4M stock offering on Nasdaq - StreetInsider
BioAffinity Technologies Closes $4 Million Direct Offering, Private Placement - Yahoo Finance
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Business Wire
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
bioAffinity Technologies plans $4M stock offering on Nasdaq - StreetInsider
bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - Business Wire
Japan intends to grant a patent for a home-collected lung cancer risk test - Stock Titan
Update: BioAffinity Technologies Prices $4 Million Registered Direct Offering - Yahoo Finance
BioAffinity Technologies Prices $4 Million Registered Direct Offering - Yahoo Finance
WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules - TradingView
More than 1,620 tests to assess lung cancer risk were delivered through Q3 2026. - Stock Titan
About 7,700 veterans are diagnosed with lung cancer yearly. A partnership aims to widen test access. - Stock Titan
Shares could be offered up to 35% below market; bioAffinity Technologies (BIAF) seeks a stockholder vote. - Stock Titan
BIAF Historical Stock Prices & Daily Price Data | bioAffinity Technologies, Inc. Common - Quiver Quantitative
Form 8K bioAffinity Technologies Inc For: 22 September By Investing.com - Investing.com Nigeria
A 2,000-patient study is evaluating a lung cancer test using at-home samples. - Stock Titan
BIAF Stock Soars As Hong Kong Patent Ignites Trading - stockstotrade.com
BIAF Stock Jolts Higher On Nasdaq Win And Federal Deal - stockstotrade.com
bioAffinity Gets Hong Kong Patent for CyPath Lung Test | BIAF Stock News - Stock Titan
bioAffinity Technologies at H.C. Wainwright conference: lung test gains traction - Investing.com Canada
bioAffinity Technologies at H.C. Wainwright conference: lung test gains traction - Investing.com India
bioAffinity Technologies at H.C. Wainwright conference: lung test gains traction - Investing.com UK
BioAffinity Technologies (NASDAQ: BIAF) Announces Presentation Materials for 2026 H.C. Wainwright Global Investment Conference - Kalkine Media
Why Did bioAffinity (NASDAQ:BIAF) Regain Nasdaq Compliance? - Kalkine Media
bioAffinity Regains Nasdaq Compliance, Maintains Capital Market Listing - The Globe and Mail
bioAffinity Regains Nasdaq Compliance, Maintains Capital Market Listing - The Globe and Mail
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
bioAffinity Technologies shares rise after Nasdaq compliance update - Quiver Quantitative
Monday's Gap-Up and Gap-Down Stock Movers: September 8 - ChartMill
BIAF Stock Jumps As Federal Deal Fuels CyPath Lung Momentum - timothysykes.com
bioAffinity Technologies regains Nasdaq compliance after bid-price recovery - TradingView
BIAF Stock Pops As CyPath Lung Wins Federal Distribution - StocksToTrade
Congrats to the folks who joined at $10. Don't forget to give me a like 😘 - Moomoo
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Yahoo Finance UK
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - Business Wire
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements - FinancialContent
Monday's Gap-Up and Gap-Down Stock Movers: September 8 - ChartMill
Top Small Cap Stocks To ConsiderSeptember 7th - MarketBeat
Small Cap Stocks To Follow NowSeptember 5th - MarketBeat
BIAF Stock Slides As bioAffinity’s Dilution And Reverse Split Reshape Trading Setup - stockstotrade.com
bioAffinity’s AI Lung-Cancer Stock Jumped Nearly 48% After a Reverse Split. What Would Have to Go Right? - Yahoo Finance
bioAffinity Technologies to Present Corporate Update at Conference - The Globe and Mail
Bioaffinity Technologies Inc (BIAF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
1.83%
자본화:
|
볼륨(24시간):